

International Diabetes Guidelines Face to Face

Anita L R Saldanha,¹ Ana Paula Pantoja Margeotto,¹ André Luis Valera Gasparoto,² Rafaela Cristina Goebel Winter Gasparoto,¹ Victoria Pantoja Margeotto,¹ and Tania Leme da Rocha Martinez,^{1*}

1. Nephrology Department, BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil
2. Intensive Care Unit, BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil

*Correspondence: Tania Leme da Rocha Martinez

Received: 10 Jan 2026; Accepted: 15 Jan 2026; Published: 25 Jan 2026

Citation: Tania Leme da Rocha Martinez. International Diabetes Guidelines Face to Face. AJMCRR. 2026; 5(1): 1-6.

Abstract

Diabetes mellitus is diagnosed by $HbA1c \geq 6.5\%$, fasting plasma glucose $\geq 126 \text{ mg/dL}$, 2-hour oral glucose tolerance test glucose $\geq 200 \text{ mg/dL}$, or random plasma glucose $\geq 200 \text{ mg/dL}$ with symptoms. Prediabetes is defined by $HbA1c 5.7\text{--}6.4\%$, fasting glucose $100\text{--}125 \text{ mg/dL}$, or 2-hour oral glucose tolerance test glucose $140\text{--}199 \text{ mg/dL}$. Glycemic targets generally aim for $HbA1c < 7\%$, with individualized goals based on age, comorbidities, and hypoglycemia risk. Recommended glucose targets include fasting levels of $80\text{--}130 \text{ mg/dL}$ and postprandial levels $< 180 \text{ mg/dL}$. Lifestyle management emphasizes at least 150 minutes of weekly physical activity, 5-10% weight loss, healthy dietary patterns, adequate sleep, and stress control. Metformin remains first-line therapy for type 2 diabetes, with Sodium-Glucose Cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists preferred in patients with cardiovascular disease, heart failure, chronic kidney disease, or weight-loss goals. Insulin is indicated for severe hyperglycemia or treatment failure. Comprehensive care includes blood pressure control ($<130/80 \text{ mmHg}$), statin therapy based on cardiovascular risk, routine screening for kidney disease, retinopathy, neuropathy, and foot complications, and adherence to adult vaccination schedules. Continuous glucose monitoring is increasingly recommended, and special populations such as pregnancy and type 1 diabetes require tailored glycemic targets and insulin-based management.

Keywords: Diabetes, Fasting glycemia, Post prandial glycemia, Glycated hemoglobin, Consensus.

Abbreviations

GLP-1 Ras: Glucagon-Like Peptide-1 receptor agonists

HbA1c: Hemoglobin A1c - Glycated Hemoglobin

SGLT2: Sodium-Glucose Cotransporter 2

Introduction

This review encompasses the key guidelines bringing together the most relevant recommendations into a single, coherent clinical summary. To be precise, in this document, the recommendations are from: American Diabetes Association Standards of Care (2024-2025); American Heart Association/American College of Cardiology Cardiovascular Risk Guidelines; Kidney Disease: Improving Global Outcomes Diabetes – Kidney Disease Guidelines; American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) and Obesity Guidelines; American College of Obstetricians and Gynecologists (ACOG) Pregnancy/Gestational Diabetes Guidelines; International Working Group on the Diabetic Foot (IWGDF) Diabetic Foot Guidelines; Centers for Disease Control and Prevention (CDC) Adult Vaccination Recommendations; International Time-in-Range Consensus (CGM) and World Health Organization (WHO) Diabetes Classification (1-25).

Prediabetes is defined by an HbA1c level between 5.7% and 6.4%, a fasting plasma glucose level ranging from 100 to 125 mg/dL, or a plasma glucose level between 140 and 199 mg/dL two hours after a 75 g oral glucose tolerance test, while a random plasma glucose test with symptoms of hyperglycemia is not applicable. In contrast, overt diabetes mellitus is diagnosed when the HbA1c level is 6.5% or higher, fasting plasma glucose is 126 mg/dL or greater, plasma glucose is 200 mg/dL or higher two hours after a 75 g oral glucose tolerance test, or a random plasma glucose level of 200 mg/dL or greater is present in association with symptoms of hyperglycemia.

Diabetes mellitus is diagnosed when any of the following criteria are met, preferably confirmed on

two separate days unless classic symptoms of hyperglycemia are present together with a random plasma glucose level \geq 200 mg/dL: hemoglobin A1c (HbA1c) \geq 6.5%, fasting plasma glucose \geq 126 mg/dL, a 2-hour plasma glucose level \geq 200 mg/dL during an oral glucose tolerance test (OGTT), or a random plasma glucose level \geq 200 mg/dL in the presence of symptoms.

Glycemic targets according to general American Diabetes Association recommendations include an HbA1c level of less than 7% for most adults, a more stringent target of less than 6.5% for young, healthy individuals at low risk of hypoglycemia, and a less stringent target ranging from 7.5% to 8% for frail older adults or for those with multiple comorbidities (1-5).

Glucose goals include a fasting plasma glucose range of 80 to 130 mg/dL and a postprandial glucose level of less than 180 mg/dL measured approximately two hours after a meal.

Prediabetes is defined by an HbA1c level between 5.7% and 6.4%, a fasting plasma glucose level ranging from 100 to 125 mg/dL, or a plasma glucose level between 140 and 199 mg/dL two hours after a 75 g oral glucose tolerance test, while a random plasma glucose test with symptoms of hyperglycemia is not applicable. In contrast, overt diabetes mellitus is diagnosed when the HbA1c level is 6.5% or higher, fasting plasma glucose is 126 mg/dL or greater, plasma glucose is 200 mg/dL or higher two hours after a 75 g oral glucose tolerance test, or a random plasma glucose level of 200 mg/dL or greater is present in association with symptoms of hyperglycemia.

Diabetes mellitus is diagnosed when any of the following criteria are met, preferably confirmed on

Lifestyle management includes engaging in at least 150 minutes per week of physical activity, combining aerobic and resistance exercises, aiming for a weight loss target of 5-10%, which has the strongest impact in individuals with type 2 diabetes, and following a healthy dietary pattern such as the Mediterranean or DASH diet or a moderate low-carbohydrate approach, with increased fiber intake and reduced consumption of processed foods, along with ensuring adequate sleep and effective stress management (22-25).

Pharmacologic therapy for type 2 diabetes begins with metformin, which remains the foundational treatment (Table 1) unless contraindicated. Subse-

quent therapy should be individualized according to the patient's clinical profile. In the presence of established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, sodium-glucose cotransporter 2 (SGLT2) inhibitors such as empagliflozin, dapagliflozin, or canagliflozin, or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide, dulaglutide, or liraglutide are preferred. When weight loss is a priority, GLP-1 RAs, which have the strongest effect, or SGLT2 inhibitors are recommended. If avoidance of hypoglycemia is essential, options include SGLT2 inhibitors, GLP-1 RAs, dipeptidyl peptidase-4 (DPP-4) inhibitors, or thiazolidinediones (TZDs). When cost is a major concern, sulfonylureas or pioglitazone may be considered.

Lipid management in diabetes includes the use of statins for all individuals aged 40 years or older, in accordance with American Diabetes Association recommendations. Moderate-intensity statins are indicated for patients at moderate cardiovascular risk, while high-intensity statins are recommended for those with high cardiovascular risk or established atherosclerotic cardiovascular disease. Corresponding LDL cholesterol targets are less than 100 mg/dL for individuals at moderate risk and less than 55 mg/dL for those with established atherosclerotic cardiovascular disease (1-5,7).

Table 1. Test criteria prediabetes overt diabetes mellitus test.

TEST CRITERIA	PREDI-ABETES	OVERT DIABETES MELLITUS
Hemoglobin A1c	5.7% to 6.4%	≥ 6.5%
Fasting plasma glucose test (mg/dL)	100 to 125	≥ 126
Plasma glucose after 75 g oral glucose tolerance test	140 to 199	2 hours: ≥ 200
Random plasma glucose test with symptoms of hyperglycemia (mg/dL)	Not applicable	≥ 200

In type 2 diabetes mellitus, insulin therapy is indicated in patients with an HbA1c level greater than 10%, the presence of catabolic symptoms, or failure to achieve glycemic control with multiple non-insulin agents. Treatment is typically initiated with basal insulin at a dose of 0.1-0.2 units per kilogram per day, followed by gradual titration to reach glycemic targets (12-13).

Blood pressure targets include a goal of less than 130/80 mmHg for most individuals, with angiotensin-converting enzyme inhibitors or angiotensin

Diabetic kidney disease management includes annual screening of estimated glomerular filtration rate and urine albumin levels, the use of SGLT2 inhibitors in patients with an estimated glomerular filtration of at least 20 mL/min, the addition of finerenone in cases of persistent albuminuria, and maintenance of blood pressure below 130/80 mmHg with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (8,9).

Diabetic retinopathy management includes an annual dilated eye examination, with longer screening intervals permitted if previous examinations have been normal and the condition remains stable.

Neuropathy and foot care management include an annual assessment of sensory function using tools such as monofilament testing and vibration perception, routine patient education on foot care, and

appropriate treatment of neuropathic pain with agents such as duloxetine, pregabalin, or gabapentin.

Vaccination recommendations include annual influenza vaccination, pneumococcal vaccination with either PCV20 or a sequential regimen of PCV13 followed by PPSV23, hepatitis B vaccination for all adults younger than 60 years with COVID-19 booster doses according to local schedules, and herpes zoster vaccination for individuals aged 50 years or older (19-21).

In diabetes care for 2024-2025, continuous glucose monitoring is recommended for all individuals with type 1 diabetes and for those with type 2 diabetes who are using basal insulin or multiple daily insulin injections, with treatment success assessed by achieving a time in range greater than 70% within the glucose range of 70-180 mg/dL.

Key guidelines for the management of type 1 diabetes include the use of a basal-bolus insulin regimen at all times, preference for continuous glucose monitoring whenever possible, carbohydrate counting as the standard approach to meal planning, and an HbA1c target of less than 7%, or less than 6.5% in young individuals at low risk of hypoglycemia.

According to the American Diabetes Association 2025 recommendations, prevention of foot complications and amputations includes performing an annual foot examination, increasing the frequency of assessments to every 3-6 months in high-risk patients, providing structured patient education to reduce the risk of foot ulceration, and using antibiotics only when an active infection is present (17-18).

In diabetes and pregnancy, the recommended HbA1c target is less than 6% when it can be

achieved safely. Glycemic targets include a fasting plasma glucose level below 95 mg/dL, a 1-hour postprandial glucose level below 140 mg/dL, and a 2-hour postprandial glucose level below 120 mg/dL. Insulin is the preferred treatment during pregnancy, while oral glucose-lowering agents are generally avoided (15-16).

The annual screening schedule for individuals with diabetes includes measurement of HbA1c two to four times per year, assessment of urine albumin filtration rate once per year, a lipid panel once per year, an annual foot examination, and a yearly dilated eye examination.

Acknowledgments

None.

Conflict of interest

None.

References

1. American Diabetes Association. Standards of Care in Diabetes-2024. *Diabetes Care*. 2024; 47(Suppl 1):S1-S321. doi: 10.2337/dc24-SINT
2. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2025. *Diabetes Care*. 2025; 48(Suppl. 1). doi:10.2337/dc25-SINT
3. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. *Diabetes Care*. 2024; 47(Suppl 1):S20-S42. doi: 10.2337/dc24-S002
4. American Diabetes Association Professional Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-

2024. *Diabetes Care.* 2024; 47(Suppl 1):S111-S125. doi: 10.2337/dc24-S006

5. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. *Diabetes Care.* 2024; 47 (Suppl 1):S158-S178. doi: 10.2337/dc24-S009

6. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2019; 73(24):e285-e350. doi: 10.1016/j.jacc.2018.11.003

7. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension.* 2018; 71(6):e13-e115. doi: 10.1161/HYP.0000000000000065

8. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney Int.* 2022; 102(5S):S1-S127. doi: 10.1016/j.kint.2022.06.008

9. Navaneethan SD, Zoungas S, Caramori ML, et al. Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update. *Ann Intern Med.* 2023; 176(3):I20-I35. doi: 10.7326/M22-2904

10. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations from the International Consensus on Time in Range. *Diabetes Care.* 2019; 42(8):1593-1603. doi: 10.2337/dci19-0028

11. Danne T, Nimri R, Battelino T, et al. International Consensus on Use of Continuous Glucose Monitoring. *Diabetes Care.* 2017; 40 (12):1631-1640. doi: 10.2337/dc17-1600

12. American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. *Diabetes Care.* 2024; 47 (Suppl 1):S179-S218. doi:10.2337/dc24-S010

13. Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update. *Endocr Pract.* 2023; 29(5):305-340. doi: 10.1016/j.eprac.2023.02.001

14. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological Management of Obesity: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2015; 100(2):342-362. doi: 10.1210/jc.2014-3415

15. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. *Obstet Gynecol.* 2018; 131 (2):e49-e64. doi: 10.1097/AOG.0000000000002501

16. American Diabetes Association Professional Practice Committee; 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes - 2024. *Diabetes Care.* 2024; 47(Suppl 1):S282-S294. <https://doi.org/10.2337/dc24-S015>

17. Schaper NC, van Netten JJ, Apelqvist J, et al. Practical Guidelines on the Prevention and Management of Diabetes-Related Foot Disease (IWGDF 2023 update). *Diabetes Metab Res Rev.* 2023; 40(3):e3657. doi: 10.1002/dmrr.3657

18. Bus SA, Armstrong DG, Crews RT, et al. Guidelines on Offloading Foot Ulcers in Persons With Diabetes (IWGDF 2023 update). *Diabetes Metab Res Rev.* 2024; 40(3):e3647. doi: 10.1002/dmrr.3647

19. Murthy N, Wodi AP, McNally VV, et al. Recommended Adult Immunization Schedule — United States, 2024. *MMWR Morb Mortal Wkly Rep.* 2024; 73(1):11-15. doi: 10.15585/mmwr.mm7301a3

20. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Use of Hepatitis B Vaccination for Adults with Diabetes Mellitus: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep.* 2011; 60(50):1709-1711. doi:10.15585/mmwr.mm6050a4.

21. Kobayashi M, Pilishvili T, Farrar JL, et al. Pneumococcal Vaccine for Adults Aged ≥ 19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. *MMWR Recomm Rep* 2023; 72 (No. RR-3):1-39. doi: <http://dx.doi.org/10.15585/mmwr.rr7203a1>

22. Colberg SR, Sigal RJ, Yardley JE, et al. Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. *Diabetes Care.* 2016; 39(11):2065-2079. doi:10.2337/dc16-1728

23. World Health Organization. WHO Guidelines on Physical Activity and Sedentary Behaviour. Geneva: World Health Organization; 2020. ISBN: 9789240014886.

24. World Health Organization. Global Report on Diabetes. Geneva: World Health Organization; 2016. ISBN 978-9241565257

25. World Health Organization. Classification of Diabetes Mellitus. Geneva: World Health Organization; 2019. ISBN 978-92-4-151570-2